周期性复发：肛门癌循环肿瘤HPV DNA动力学。

IF 10 1区医学 Q1 ONCOLOGY

Clinical Cancer Research Pub Date : 2025-04-15 DOI:10.1158/1078-0432.ccr-25-0421

Aron Bercz,Daniel L Faden,J Joshua Smith,Paul B Romesser

{"title":"周期性复发：肛门癌循环肿瘤HPV DNA动力学。","authors":"Aron Bercz,Daniel L Faden,J Joshua Smith,Paul B Romesser","doi":"10.1158/1078-0432.ccr-25-0421","DOIUrl":null,"url":null,"abstract":"Detection of circulating tumor human papillomavirus DNA (ctHPVDNA) three months after completing definitive chemoradiation for localized anal squamous cell carcinoma associates with disease recurrence and inferior recurrence-free survival. These findings provide valuable insights into the temporal significance of ctHPVDNA detection in anal cancer and its potential implications for early intervention.","PeriodicalId":10279,"journal":{"name":"Clinical Cancer Research","volume":"116 1","pages":""},"PeriodicalIF":10.0000,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clocking Recurrence: Circulating Tumor HPV DNA Kinetics in Anal Cancer.\",\"authors\":\"Aron Bercz,Daniel L Faden,J Joshua Smith,Paul B Romesser\",\"doi\":\"10.1158/1078-0432.ccr-25-0421\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Detection of circulating tumor human papillomavirus DNA (ctHPVDNA) three months after completing definitive chemoradiation for localized anal squamous cell carcinoma associates with disease recurrence and inferior recurrence-free survival. These findings provide valuable insights into the temporal significance of ctHPVDNA detection in anal cancer and its potential implications for early intervention.\",\"PeriodicalId\":10279,\"journal\":{\"name\":\"Clinical Cancer Research\",\"volume\":\"116 1\",\"pages\":\"\"},\"PeriodicalIF\":10.0000,\"publicationDate\":\"2025-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1158/1078-0432.ccr-25-0421\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1158/1078-0432.ccr-25-0421","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在局部肛门鳞状细胞癌完成明确化疗三个月后检测到循环肿瘤人乳头状瘤病毒DNA（ctHPVDNA）与疾病复发和无复发生存率较低有关。这些发现为了解ctHPVDNA检测在肛门癌中的时间意义及其对早期干预的潜在影响提供了宝贵的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clocking Recurrence: Circulating Tumor HPV DNA Kinetics in Anal Cancer.

Detection of circulating tumor human papillomavirus DNA (ctHPVDNA) three months after completing definitive chemoradiation for localized anal squamous cell carcinoma associates with disease recurrence and inferior recurrence-free survival. These findings provide valuable insights into the temporal significance of ctHPVDNA detection in anal cancer and its potential implications for early intervention.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.